Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247567 | 0.96 | IDO1 (0.53) | IDO1MEN1KMT2AHRH3LMNA | |
| SCHEMBL299485 | 0.94 | L3MBTL1 (0.51) | IDO1MEN1KMT2AHRH3SIGMAR1 | |
| SCHEMBL8729752 | 0.92 | TDP1 (0.54) | IDO1MEN1KMT2ASIGMAR1MAOA | |
| SCHEMBL9021195 | 0.92 | TDP1 (0.54) | IDO1MEN1KMT2ASIGMAR1MAOA | |
| SCHEMBL511327 | 0.92 | TDP1 (0.54) | IDO1MEN1KMT2ASIGMAR1MAOA | |
| SCHEMBL8496055 | 0.92 | TDP1 (0.54) | IDO1MEN1KMT2ASIGMAR1MAOA | |
| SCHEMBL299681 | 0.92 | TDP1 (0.54) | IDO1MEN1KMT2ASIGMAR1MAOA | |
| SCHEMBL294494 | 0.86 | CA1 (0.45) | IDO1HTR2AMAOATDP1 | |
| SCHEMBL196951 | 0.86 | IDO1 (0.67) | IDO1MEN1KMT2AHRH3LMNA | |
| SCHEMBL57901 | 0.85 | IDO1 (0.55) | IDO1MEN1KMT2AHRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4252716-A | BLUE SHADES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-24 | — | — | US | claimed |
| US-3991042-A | Basic azo dyestuffs containing a benzthiazole and a tetrahydroquinoline nucleus | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | claimed |
| CN-104302644-A | Thiazolecarboxamide derivatives and methods of use thereof | NIHON NOHYAKU CO LTD | 2015-01-21 | — | — | CN | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8598162-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| WO-2013041482-A1 | SIDE CHAIN-FUNCTIONALIZED PEG | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2013-03-28 | — | — | WO | disclosed |
| CN-102850336-A | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMA CO LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102702182-A | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-10-03 | — | — | CN | disclosed |
| CN-102558140-A | Derivatives of 4-piperazin-1-1-yl-4-benzo [b] thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-07-11 | — | — | CN | disclosed |
| EP-2287162-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2287161-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| WO-2000023425-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023445-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023415-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000023416-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| EP-0500853-B1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM | THOMAE GMBH DR K (DE) | 1996-12-27 | — | — | EP | disclosed |
| US-5393774-A | Antispasmodic agents | PIEPER HELMUT (DE) | 1995-02-28 | — | — | US | disclosed |
| EP-0500853-A1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM. | THOMAE GMBH DR K (DE) | 1992-09-02 | — | — | EP | disclosed |
| WO-1992004316-A1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1992-03-19 | — | — | WO | disclosed |
| EP-0046590-A2 | Phen(alk)oxy-substituted oxirane-carboxylic acids, process for their preparation, their use and drugs containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | IDO1 1375/4885MEN1 2715/4885KMT2A 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.